A 78-year-old patient in Japan has unresectable locally advanced non-small cell lung cancer and is being considered for concurrent chemoradiotherapy. The team discusses daily low-dose carboplatin versus weekly carboplatin plus nab-paclitaxel with thoracic radiotherapy.
What does the evidence in this abstract support for this patient population?
